phase 2a dose escalation study to investigate the safety, PK, PD, and efficacy of CC-220 in patients with SLE. Forty-two (42) adult SLE subjects fulfilling SLE ACR criteria, having a history of SLE for ≥ 6 months and a baseline Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥ 4 were randomized to placebo or 1 of 4 escalating doses of CC-220 (0.3 mg QOD, 0.3 mg QD, 0.6/0.3 mg alternating QD, or 0.6 mg QD).

Results: CC-220 concentration-time profiles demonstrated dose proportionality between cohorts, with moderate accumulation in the non-alternating dose cohort. CC-220 significantly reduced total CD20+ B cells by as much as 96%, immature B cells by as much as 91.2%, switched memory B cells by as much as 81.4%, BAFFR+ B cells by as much as 67.5%, and plasmacytoid dendritic cells (pDCs) by as much as 86.5% (Day 85 median percent change from baseline). Whereas reductions in B cells were observed, CD4+ as well as CD8+ T cells increased, and the rise in T cells paralleled the observed increase in plasma cells in those subjects who received the highest dose (0.6 mg). An exposure-response analysis demonstrated decreasing B cells, pDCs and neutrophils with increased exposure to CC-220.

Conclusions: It was determined that 0.3 mg QD to 0.6/0.3 mg alternating QD reduced concentrations of B cells and pDCs while avoiding neutropenia. These findings, in combination with the PK, safety, and exploratory efficacy data, support continued development of CC-220 in SLE.

Disclosure of Interest: A. Gaudy Shareholder of: Celgene, Employee of: Celgene, Y. Ye Shareholder of: Celgene, Employee of: Celgene, S. Korish Shareholder of: Celgene, Employee of: Celgene, D. Hough Shareholder of: Celgene, Employee of: Celgene, M. Weiswasser Shareholder of: Celgene, Employee of: Celgene, S. Choi Shareholder of: Celgene, Employee of: Celgene, R. Furie Consultant for: Celgene, V. Werth Grant/research support from: Celgene, Consultant for: Celgene, P. Schafer Shareholder of: Celgene, Employee of: Celgene
DOI: 10.1136/annrheumdis-2017-eular.3036

SAT0226 A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2

I. Catlett¹, U. Aras², Y. Liu³, D. Bei², I. Girgis², B. Murthy², M. Honczarenko¹, S. Rose¹. ¹Innovative Clinical Development; ²Clinical Pharmacology; ³Global Biometric Sciences, Bristol-Myers Squibb, Princeton, United States

Background: Tyrosine kinase 2 (Tyk2) is a member of the JAK family that phosphorylates STAT proteins downstream of the IL-12, IL-23 and the Type I interferon receptor. Tyk2 genetic variants have been linked to multiple autoimmune diseases,¹ with a deactivating coding variant conferring significant protection against multiple immune-mediated disorders including systemic lupus erythematosus (SLE).² Selective pharmacologic inhibition of Tyk2 has proven daunting, given the high degree of similarity among JAK catalytic domains. Using a novel approach, we have developed BMS-986165, a highly selective and potent small molecule inhibitor, which blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein. Lupus-like disease is strongly inhibited in NZB/W mice treated with BMS-986165. Together, these data establish Tyk2 as a highly promising therapeutic target for SLE.

Objectives: We report the first evidence of safety, pharmacokinetics (PK), target engagement (TE), and pharmacodynamic activity (PD) of BMS-986165, a novel inhibitor of Tyk2.

Methods: Safety, PK, TE, and PD were assessed in a randomized, double-blind, single and multiple ascending dose study of 108 (83 active: 25 placebo) healthy participants (NCT02534636). Target engagement was assessed by an ex vivo assay, IL-12 and IL-18 induced IFN γ production. Roferon-A was administered to assess in vivo pharmacodynamic effects of BMS-986165 on physiological manifestations of IFN exposure and on IFN-regulated gene (IRG) expression.

Results: BMS-986165 was safe and overall well-tolerated. There were no serious adverse events and the frequency of non-serious adverse events were similar in the active (75%) and placebo (76%) groups. The most frequently reported adverse events by preferred term were headache (23% active versus 28% placebo), nausea (12% active versus 8% placebo), rash (12% active versus 8% placebo), and upper respiratory tract infection (11% active versus 12% placebo). After oral administration, BMS-986165 was rapidly absorbed and exhibited an apparent elimination half-life of 8–15 hours. Modest accumulation (1.4x–1.9x) was observed after multiple dosing. BMS-986165 inhibited IL-12/IL-18-induced IFN γ production in ex vivo assays in a dose and concentration dependent manner. Following an in vivo challenge with a clinical dose of Interferon- α -2A, BMS-986165 demonstrated dose-dependent inhibition of lymphocyte count decreases and expression of 53 IRGs in blood (Figure 1).

Conclusions: BMS-986165 is a safe and potent Tyk2 inhibitor with clear evidence of ex vivo and in vivo biologic activity in healthy participants, and the potential for once daily dosing. Overall, inhibition of IL-12/23 and type I IFN pathways support further testing of BMS-986165 in diseases such as lupus and psoriasis. A Phase 2 study in patients with moderate-to-severe psoriasis is ongoing (NCT02931838).

References:

- Liang Y, Zhu Y, Xia Y, Peng H, Yang XK, et al. Therapeutic potential of tyrosine kinase 2 in autoimmunity. *Expert Opin Ther Targets*. 2014 May;18(5):571–80.
- Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, et al. Resolving

Figure 1: In vivo pharmacodynamic challenge

TYK2 locus genotype-to-phenotype differences in autoimmunity. *Sci Transl Med*. 2016 Nov 2;8(363):363ra149.

Disclosure of Interest: I. Catlett Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, U. Aras Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Y. Liu Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, D. Bei Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, I. Girgis Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, B. Murthy Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, M. Honczarenko Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Rose Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb
DOI: 10.1136/annrheumdis-2017-eular.3809

SAT0227 HEALTH CARE UTILIZATION AND COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE UNITED STATES: SYSTEMATIC REVIEW

E. Hammond¹, I.B. Murimi², D.H. Lin², H. Kan², J. Tierce², X. Wang¹, H. Nab³, B. Desta¹, G.C. Alexander². ¹AstraZeneca, Gaithersburg, MD; ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; ³AstraZeneca, Cambridge, United Kingdom

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects as many as 518 persons per 100,000 people in the United States and Europe.

However, much of our current knowledge on SLE health care utilization and costs is based on analyses conducted prior to 2011, after which important treatment innovations (e.g., belimumab and, to some extent, rituximab) and health care marketplace changes occurred in the United States.

Objectives: The objectives of this systematic review were to summarize the patterns of health care utilization for patients with SLE and to characterize the direct and indirect costs of SLE by disease severity in the United States.

Methods: We conducted a systematic literature review of adult patients with SLE in the United States by searching PubMed and Embase for relevant articles written in English and published during January 2000–April 2016. We examined health care utilization measures including emergency department (ED) visits, hospitalizations, outpatient visits, medication use, and adherence. We restricted the analysis to observational studies, excluding case reports and commentaries. All monetary costs were converted to US 2016 \$.

Results: In total, 4,700 articles were screened, 388 articles were retained for full-text review, and 38 articles were selected for inclusion in this report. Across these 38 studies, mean patient ED utilization rates were 0.9–2.1 visits/year. Mean hospitalization rates were 0.4–2.6 inpatient stays/year, with 5–6 days/stay on average. Patients averaged 10–19 total physician visits/year. More than 90% of patients with SLE had ≥ 1 visit to a primary care provider annually. In addition, 51–71% visited rheumatologists, and 6–7% visited nephrologists. Health care resource use with respect to ED visits, hospitalization rates, inpatient length of stay, and ambulatory care was greater for patients with lupus nephritis than for patients with SLE without nephritis. Mean annual direct costs from various studies ranged between \$15,171–\$88,445 for patients with SLE regardless of the presence of nephritis. Nearly all studies indicated that mean direct medical costs were greater for patients with moderate or severe disease (\$22,300–\$83,000) than those with mild disease (\$8,900–\$15,000). Mean annual pharmacy costs ranged between \$1,572–\$13,138, accounting for 19–23% of total direct costs, and medical costs ranged between \$21,290–\$82,854. On average, 12–49% of patients were unemployed, and the mean number of sick days/month was 2.3 days. The range of estimates of mean total direct costs for patients with SLE overall were often